Yabao Pharma and Primary Peptides sign exclusive China partnership for stroke treatment

Chinese specialty drugmaker Yabao Pharmaceutical (SSE:  600351) has entered into an exclusive license with privately held Canadian firm Primary Peptides to develop and commercialize innovative products targeting PTEN nuclear translocation for the treatment of stroke.

Under the terms of the agreement, Yabao receives exclusive rights to develop and commercialize in China, Taiwan and Hong Kong while Primary Peptides, a University of British Columbia spin-off, retains rights in all other markets. Financial terms were not disclosed.  However, according to a Business Vancouver report, Primary Peptides anticipates as much as $40 million investment from Yabao.

“Yabao is pleased to be collaborating with Primary Peptides, a world leader in development of new peptide therapeutics in the cardiovascular and neuroscience areas," commented Peng Wang, president R&D at Yabao, adding: "This opportunity for Yabao to expand on leading research to develop innovative products is further evidence of Yabao's growing commitment to partner the best science to treat serious diseases in